FDA Starts Real‑Time Trial Pilot with AstraZeneca
SkimNews Take
Real-time data access could shift FDA's role from post-hoc gatekeeper to active, in-process participant in drug development, potentially accelerating approvals by addressing issues proactively.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA launches real‑time trial framework to cut the 45% idle period between Phase 1 and final submission.
- AstraZeneca partners with MD Anderson Cancer Center and University of Pennsylvania on a proof‑of‑concept trial that streams safety and efficacy signals to the FDA in real time.
- Amgen joins a second real‑time trial, and the FDA will expand the pilot program this summer to test cloud‑based monitoring and set standardized success metrics.
Why it matters: Patients and pharma firms gain faster access to therapies; cutting the 45% idle period shaves years off development timelines and reduces R&D costs, while regulators gain earlier safety signals, improving public health outcomes.
